# Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

> **NCT04130516** · PHASE1,PHASE2 · RECRUITING · sponsor: **Linnaeus Therapeutics, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
- **BIOLOGICAL:** Pembrolizumab - anti-PD-1 antibody

## Key facts

- **NCT ID:** NCT04130516
- **Lead sponsor:** Linnaeus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-21
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-15
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04130516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04130516, "Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04130516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*